论文部分内容阅读
目的通过检测慢性阻塞性肺疾病(COPD)急性加重期合并心衰患者血清中B型尿钠肽(BNP)和C反应蛋白(CRP)浓度变化,旨在探讨BNP和CRP在COPD急性加重期合并心衰患者中的临床意义。方法采用微粒子酶法和酶联免疫吸附法,对80例治疗前不同程度COPD急性加重期合并心衰患者BNP和CRP浓度进行检测,并与治疗后COPD急性加重期合并心衰患者(即稳定期)及对照组(健康人群)浓度作比较。结果治疗前COPD急性加重期合并心衰患者BNP和CRP较对照组高,差异有统计学意义(P<0.01)。随着病情的加重,血清中BNP和CRP水平也显著升高。治疗后COPD急性加重期合并心衰患者与对照组比较,差异有统计学意义(P<0.05)。结论血清中BNP和CRP可作为判断COPD急性加重期合并心衰患者病情严重程度及估计预后的指标之一。
Objective To detect the changes of serum BNP and C-reactive protein (CRP) concentrations in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) and to explore the relationship between BNP and CRP in acute exacerbation of COPD Clinical Significance in Patients with Heart Failure. Methods The levels of BNP and CRP in 80 patients with acute exacerbation of COPD before and after heart failure were measured by microparticle enzyme and enzyme-linked immunosorbent assay, and compared with those of patients with heart failure after stable exacerbation of COPD ) And control group (healthy population). Results The BNP and CRP in patients with acute exacerbation of COPD before treatment were significantly higher than those in control group (P <0.01). As the disease progresses, serum BNP and CRP levels also significantly increased. After treatment, acute exacerbation of COPD patients with heart failure compared with the control group, the difference was statistically significant (P <0.05). Conclusion Serum BNP and CRP may be used as indicators to judge the severity of the patients with acute exacerbation of COPD and prognosis.